Tesamorelin – Stabilised GHRH Analogue for Research

Tesamorelin is an advanced synthetic analogue of human growth hormone-releasing hormone, also known as GHRH or growth hormone-releasing factor. It contains the complete 44-amino-acid sequence of human GRF with a specialised N-terminal trans-3-hexenoyl modification. This molecular modification supports improved resistance to rapid enzymatic degradation and gives Tesamorelin a more stable research profile than naturally occurring GHRH. Its clearly defined structure makes Tesamorelin particularly relevant for professional laboratory studies involving GHRH receptor activity, pituitary signalling, endogenous growth hormone release, the GH–IGF-1 axis and stabilised peptide development. Tesamorelin is supplied as a premium lyophilised research material in a securely sealed vial with clear batch information, professional packaging and fast order processing from Peptides Divas.

Vigtige produktfunktioner

• Synthetic human GHRH analogue
• Complete 44-amino-acid peptide sequence
• Also known by the research designation TH9507
• Specialised N-terminal hexenoyl modification
• Designed for improved molecular stability
• Relevant for GHRH receptor research
• Suitable for pituitary signalling studies
• Useful for GH and IGF-1 pathway research
• Leveres som frysetørret forskningsmateriale
• Tydelige batchspecifikke produktoplysninger
• Sikker og diskret emballage
• Hurtig og sporbar levering i Europa

What Is Tesamorelin?

Tesamorelin is a synthetic peptide based on the complete amino-acid sequence of naturally occurring human growth hormone-releasing hormone. Natural GHRH is produced in the hypothalamus and communicates with specialised receptors located on somatotroph cells within the anterior pituitary. This signalling system is involved in regulating the synthesis and pulsatile release of endogenous growth hormone. Naturally occurring GHRH is rapidly broken down by enzymes. Tesamorelin contains an N-terminal trans-3-hexenoyl group attached to its tyrosine residue, creating a stabilised GHRH analogue suitable for extended peptide and receptor research.

Molekylstruktur

Tesamorelin contains 44 amino acids and retains the complete sequence of human GRF. Its structural characteristics include:

• Complete human GRF 1–44 sequence
• N-terminal tyrosine residue
• Trans-3-hexenoyl molecular modification
• C6 carbon chain containing a double bond
• Stabilised synthetic peptide structure
• GHRH receptor agonist activity
• Approximate molecular weight of 5.1 kDa
• Commonly prepared and analysed as an acetate salt

The hexenoyl modification differentiates Tesamorelin from unmodified human GHRH and shorter GHRH fragments.

GHRH Receptor Research

Tesamorelin is primarily studied in relation to the growth hormone-releasing hormone receptor. The GHRH receptor is a G-protein-coupled receptor expressed mainly on pituitary somatotroph cells. Activation of this receptor initiates intracellular signalling associated with growth hormone synthesis and secretion. Potential areas of laboratory research include:

• GHRH receptor binding
• Receptoraktivering
• Ligand-receptor-interaktioner
• Cyklisk AMP-signalering
• Intracellular calcium pathways
• Pituitary somatotroph activity
• Receptorinternalisering
• Receptorfølsomhed
• Concentration-response relationships
• Comparative GHRH analogue pharmacology

The exact experimental conditions and analytical methods should be established by the qualified laboratory conducting the research.

Pituitary Signalling Research

The anterior pituitary is an important endocrine signalling centre responsible for releasing several protein and peptide hormones. Tesamorelin may be relevant for controlled laboratory studies involving:

• Somatotroph-cell signalling
• Endogenous growth hormone release
• Pulsatile hormone secretion
• Pituitary receptor expression
• Intracellulær signaltransduktion
• Hormone-release kinetics
• Hypothalamic–pituitary communication
• Endocrine feedback mechanisms
• Comparative pituitary-cell assays
• GHRH-mediated cellular responses

Tesamorelin stimulates the GHRH pathway rather than acting as recombinant growth hormone itself.

GH–IGF-1 Axis Research

The growth hormone and insulin-like growth factor 1 axis forms an interconnected endocrine signalling network. GHRH receptor activation in the pituitary can influence endogenous growth hormone secretion. Growth hormone subsequently participates in signalling associated with IGF-1 production and broader endocrine feedback systems. Tesamorelin may therefore be studied in relation to:

• Growth hormone pulsatility
• GH secretion patterns
• IGF-1-associated signalling
• Endocrine feedback loops
• Hypothalamic–pituitary communication
• Hormone biomarker analysis
• Metabolic signalling pathways
• Protein-turnover mechanisms
• Comparative endocrine models
• Time-dependent hormone responses

These pathways describe areas of scientific interest and should not be interpreted as guaranteed effects from a non-pharmaceutical research material.

Stabilised Peptide Research

The N-terminal hexenoyl modification makes Tesamorelin particularly relevant for research into peptide stabilisation and molecular engineering. Potential research topics include:

• Resistance to enzymatic degradation
• N-terminal peptide modification
• Molecular half-life extension
• Peptide clearance
• Struktur-aktivitetsforhold
• Long-acting peptide design
• Peptide pharmacokinetics
• Modified GHRH analogues
• Molekylær stabilitet
• Peptide formulation development

Researchers may compare Tesamorelin with native GHRH, sermorelin, Modified GRF 1–29 or other GHRH-related compounds.

Tesamorelin Versus Sermorelin

Tesamorelin and sermorelin are both related to human GHRH, but they are not identical compounds.

Karakteristisk	Tesamorelin
Peptide sequence	Human GRF 1–44
Peptidlængde	44 amino acids
Molecular modification	N-terminal trans-3-hexenoyl group
Primary receptor	GHRH receptor
Research profile	Stabilised full-length GHRH analogue
Alternative designation	TH9507

Sermorelin generally refers to the shorter GHRH 1–29 sequence and does not contain the same hexenoyl modification.

Tesamorelin Versus CJC-1295

Tesamorelin and CJC-1295 are both synthetic GHRH-related peptides, but their structures and stabilisation strategies differ. Tesamorelin contains the full 44-amino-acid human GRF sequence with an N-terminal hexenoyl modification. CJC-1295 with DAC uses a different modified peptide sequence and an albumin-binding Drug Affinity Complex. Researchers should not treat these compounds as interchangeable and should verify the exact product identity through batch-specific analytical documentation.

Metabolic Pathway Research

The GH–IGF-1 axis interacts with multiple metabolic and endocrine systems. Tesamorelin may be relevant for laboratory models involving:

• Lipidrelateret signalering
• Glukose-homeostase-veje
• Protein metabolism
• Hepatic signalling
• Adipocyte biology
• Endocrine–metabolic communication
• Cellular energy regulation
• Hormone-responsive gene expression
• Metabolic biomarker analysis
• Comparative peptide research

Research results can vary according to the biological model, concentration, exposure duration and analytical method.

Potentielle forskningsanvendelser

Tesamorelin may be suitable for controlled scientific research involving:

• GHRH receptor pharmacology
• Pituitary somatotroph signalling
• Endogenous growth hormone secretion
• Growth hormone pulsatility
• GH–IGF-1 axis research
• Hypothalamic–pituitary communication
• Endocrine feedback mechanisms
• Peptide stabilisation
• N-terminal molecular modification
• Struktur-aktivitetsforhold
• Metabolic signalling
• Analytisk peptidkarakterisering
• Kromatografisk analyse
• Massespektrometrianalyse
• Stabilitets- og nedbrydningstest
• Comparative GHRH analogue research

The receiving laboratory is responsible for determining and validating appropriate concentrations, controls and analytical procedures.

Analytisk forskning

Tesamorelin may be suitable for professional analytical applications involving:

• Højtydende væskekromatografi
• Væskekromatografi-massespektrometri
• Bekræftelse af peptididentitet
• Molekylvægtanalyse
• Amino-acid-sequence verification
• Renhedsvurdering
• Stabilitetstestning
• Nedbrydningsprofilering
• Opløselighedsvurdering
• Sammenligning af referencematerialer
• Formuleringskompatibilitet
• Udvikling af analytiske metoder

Because Tesamorelin contains an N-terminal lipid modification, analytical methods should be validated specifically for this compound.

Produktspecifikationer

Produktkarakteristik	Information
Produktnavn	Tesamorelin
Alternative designation	TH9507
Produktkategori	Syntetisk forskningspeptid
Forbindelsestype	Stabilised GHRH analogue
Peptidlængde	44 amino acids
Strukturelt grundlag	Complete human GRF 1–44 sequence
Molecular modification	N-terminal trans-3-hexenoyl group
Primary research target	GHRH receptor
Main research pathway	Growth hormone and IGF-1 axis
Approximate molecular weight	5.1 kDa
Form	Frysetørret forskningsmateriale
Præsentation	Sikkert forseglet forskningsflaske
Dokumentation	Batchspecifikke analytiske oplysninger
Emballage	Sikker og diskret emballage
Tilsigtet anvendelse	Videnskabelig, analytisk og laboratorieforskning

Frysetørret forskningsformat

Tesamorelin is supplied as a lyophilised research material in a securely sealed vial. Lyophilisation removes moisture and helps support peptide stability during controlled storage and transportation. Minor differences in physical appearance may occur because of product quantity, production conditions and residual moisture. Physical appearance alone should not be used to establish product identity, purity or analytical quality. Researchers should review the documentation associated with the applicable batch before beginning laboratory work.

Kvalitet og produkttransparens

Peptides Divas focuses on clearly displayed product specifications, professional handling and batch-level traceability. Available analytical information may include:

• Produktidentifikation
• Peptide sequence
• Batch- eller lotnummer
• Rapporteret renhed
• HPLC-analyse
• Massespektrometridata
• Molecular-weight information
• Testoplysninger
• Produktets udseende
• Opbevaringsanbefalinger

Dette giver forskere klare og sporbare oplysninger om det relevante produktparti.

Opbevaringsoplysninger

Store Tesamorelin in its original sealed packaging according to the conditions displayed on the product label and applicable batch documentation. Protect the research material from:

• Direkte sollys
• Overdreven varme
• Fugtighed
• Forurening
• Beskadiget emballage
• Gentagne temperaturudsving
• Unødvendig eksponering for luft

The receiving laboratory is responsible for establishing appropriate preparation, handling and storage procedures for its specific research protocol.

Why Choose Tesamorelin?

Tesamorelin provides a clearly defined and stabilised full-length GHRH analogue for advanced receptor and endocrine research. Key research advantages include:

• Complete 44-amino-acid human GRF sequence
• Specialised N-terminal hexenoyl modification
• Relevant for GHRH receptor studies
• Suitable for pituitary signalling research
• Useful for GH–IGF-1 axis models
• Valuable for peptide-stability analysis
• Suitable for comparative GHRH research
• Praktisk frysetørret præsentation
• Tydelige batchspecifikke produktoplysninger

Hvorfor bestille fra Peptides Divas?

Peptides Divas kombinerer omhyggeligt udvalgte forskningsmaterialer med hurtig, pålidelig og professionel service. Kunderne drager fordel af:

• Tydelig viste produktspecifikationer
• Batchspecifikke analytiske oplysninger
• Hurtig ordrebehandling
• Sikker og diskret emballage
• Sporbare forsendelsesmuligheder
• Omhyggelig beskyttelse af hætteglasset
• Responsiv kundesupport
• Pålidelig europæisk levering

Choose Tesamorelin from Peptides Divas for advanced laboratory research involving GHRH receptor activity, pituitary signalling, the GH–IGF-1 axis and stabilised peptide design. For laboratory research use only. Not intended for human or veterinary use.